As known that LIN28A overexpression has been associated with low sensitivity to numerous cancer therapies including Cisplatin (Balzeau et al., 2017), so we performed the cell viability assay and showed that knockdown of LIN28A increased drug sensitivity to Cisplatin in T47D cells, which was rescued by re‐expression of LIN28A‐WT but not mutant LIN27A‐K15R (Fig. S6). Here, LIN28A is linked to cancer.